Pharmacologic treatments for covid-19 patients

Favipiravir vs Standard care/Placebo

Study Dabbous HM, Scientific Reports, 2021 has been retracted on September 18, 2021. The study was excluded from the analysis and grade assessment by October 10 the latest.


Outpatients

Forest plots
(last update: 2022-08-18)

Summary of findings
(last update: 2022-09-27)

Hospitalized patients

Forest plots
(last update: 2022-10-20)

Funnel plots
(last update: 2022-10-24)

Summary of findings
(last update: 2022-10-23)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=43

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
TCTR20200514001
Sirijatuphat R, Emerg Microbes Infect, 2022
Full text
Commentary
Mixed

Favipiravir

Standard care

RCT Patients with confirmed COVID-19 (mild) admitted to three centers in Thailand N=96
Some concerns
Details

Full description

NCT04445467
VIRCO
McMahon J, SSRN, 2022
Full text
Commentary
Commentary
Public/non profit

Favipiravir

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated at multiple centers in Australia. N=199
Low
Details

Full description

NCT04402203
Rahman SMA, Clin Infect Pract, 2022
Full text
Commentary
Private

Favipiravir

Placebo

RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 4 centers in Bangladesh. N=57
High
Details

Full description

NCT04387760
AlQahtani M, Sci Rep, 2022
Full text
Commentary
Commentary
Public/non profit

Favipiravir

Standard care

RCT Patients with confirmed COVID-19 (mild) admitted to 2 centers in Bahrain N=106
Some concerns
Details

Full description

NCT04499677
FLARE
Lowe DM, medRxiv, 2022
Full text
Commentary
Commentary
Mixed

Favipiravir

Lopinavir + Ritonavir

Lopinavir + Ritonavir + Favipiravir

Favipiravir

Placebo

Placebo

Placebo

Lopinavir + Ritonavir

RCT Outpatients with confirmed COVID-19 (asymptomatic-mild) treated by 2 centers in the UK N=240
Some concerns
Details

Full description

NCT04346628
Holubar M, Clin Infect Dis, 2022
Full text
Full text
Commentary
Commentary
Commentary
Public/non profit

Favipiravir

Placebo

RCT Outpatients with confirmed COVID-19 (asymptomatic and mild ambulatory) treated by a single center in the USA N=149
Some concerns
Details

Full description

NCT04529499; IND148286
Shenoy S, medRxiv, 2021
Full text
Full text
Commentary
Commentary
Private

Favipiravir

Placebo

RCT Patients with confirmed COVID-19 (mild to critical) admitted to 3 centers in Kuwait. N=353
Low
Details

Full description

NCT04464408
Bosaeed M, Clin Microbiol Infect, 2022
Full text
Commentary
Public/non profit

Favipiravir

Placebo

RCT Outpatients with confirmed COVID-19 (mild-ambulatory) treated by 7 centers in Saudi Arabia N=245
Some concerns
Details

Full description

NCT04818320
Chuah CH, Clin Infect Dis, 2021
Full text
Commentary
Commentary
No specific funding

Favipiravir

Standard care

RCT Patients with confirmed COVID-19 (mild/moderate) admitted to 14 centers in Malaysia. N=500
Some concerns
Details

Full description

NCT04358549
Finberg RW, Open Forum Infect Dis, 2021
Full text
Commentary
Commentary
Mixed

Favipiravir

Standard care

RCT Patients with confirmed COVID-19 (mild-severe) admitted to 7 centers in the USA N=50
Some concerns
Details

Full description

JapicCTI-205238
Shinkai M, Infect Dis Ther, 2021
Full text
Commentary
Private

Favipiravir

Placebo

RCT Patients with confirmed COVID-19 (mild/moderate) admitted to 39 centers in Japan. N=156
Some concerns
Details

Full description

NCT04434248
Ivashchenko AA, Clin Infect Dis, 2020
Full text
Commentary
Mixed

Favipiravir 1800/800mg

Favipiravir 1600/600mg

Favipiravir 1800/800mg

Standard care

Standard care

Favipiravir 1600/600mg

RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 6 centers in Russia N=60
Some concerns
Details

Full description

NCT04333589
Zhao H, Int Immunopharmacol, 2021
Full text
Commentary
Public/non profit

Favipiravir

Standard care

RCT Outpatients whith confirmed recurrent COVID-19 (mild),isolated and treated by 5 centres in China. N=55
Some concerns
Details

Full description

NCT04501783
Ruzhentsova TA, Am J Transl Res, 2021
Full text
Full text
Commentary
Commentary
Private

Favipiravir

Standard care

RCT Outpatients and inpatients with confirmed COVID-19 (mild-moderate) treated at 10 centers in Russia N=168
Some concerns
Details

Full description

CTRI/2020/05/025114
Udwadia Z, Int J Infect Dis, 2020
Full text
Commentary
Private

Favipiravir

Standard care

RCT Patients with confirmed COVID-19 (mild/moderate) admitted to 7 centers in India N=150
Some concerns
Details

Full description

NCT04542694
Balykova L, Infektsionnye bolezn, 2020
Full text
Commentary
Private

Favipiravir

Standard care

RCT Patients with confirmed COVID-19 (moderate) admitted to 5 centers in Russia N=200
Some concerns
Details

Full description

ChiCTR2000029544
Lou Y, Eur J Pharm Sci, 2020
Full text
Commentary
Public/non profit

Favipiravir

Baloxavir marboxil

Favipiravir

Standard care

Standard care

Baloxavir marboxil

RCT Patients with confirmed COVID-19 (unclear severity) admitted to a single center in China N=30
Some concerns
Details

Full description